# A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

> **NCT06898450** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nimbus Wadjet, Inc.** · enrollment: 134 (estimated)

## Conditions studied

- Advanced Solid Tumors Cancer
- MSI-H Cancer

## Interventions

- **DRUG:** NDI-219216

## Key facts

- **NCT ID:** NCT06898450
- **Lead sponsor:** Nimbus Wadjet, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2031-10
- **Final completion:** 2031-12
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- Worldwide Clinical Trials

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06898450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06898450, "A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06898450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*